Pharmacogenetics of vitamin K antagonists: useful or hype?

Keyphrases

• Hype 100%
• Vitamin K Antagonists 100%
• Pharmacogenetics 100%
• Oral Anticoagulant Therapy 60%
• Clinical Variables 40%
• Coagulation 40%
• Anticoagulant Therapy 40%
• Patient Care 40%
• Genetic Testing 40%
• CYP2C9 40%
• Genetic Variables 40%
• Body Mass Index 20%
• Demographic Variables 20%
• Comorbidity 20%
• Thrombosis 20%
• Demographic Information 20%
• Polymorphism 20%
• Bleeding 20%
• Cost-effectiveness 20%
• Social Issues 20%
• Ethical Issues 20%
• Cytochrome P450 (CYP450) 20%
• Drug Target 20%
• Age of Information 20%
• Dose-response 20%
• Environmental Variables 20%
• Long-term Treatment 20%
• Thrombin 20%
• Dietary Intake 20%
• Coumarin 20%
• Coumarin Derivatives 20%
• Clinical Validation 20%
• Gene Polymorphism 20%
• Quality Specifications 20%
• Panacea 20%
• Optimal Composition 20%
• Ongoing Development 20%
• Unknown Information 20%
• Informative Genes 20%
• Outcome Analysis 20%
• Long-term Anticoagulation 20%
• Early Anticoagulation 20%
• Analytical Performance Specifications 20%
• Vitamin K 20%
• Pharmacogenetic Testing 20%
• Warfarin Resistance 20%
• New Anticoagulant Drugs 20%
• Vitamin K Epoxide Reductase 20%
• Pharmacological Response 20%
• VKORC1 20%
• Drug Interference 20%
• Dosing Algorithm 20%
• Adverse Health Outcomes 20%
• Inter-individual Variability 20%
• Routine Genetic Testing 20%
• Development Validation 20%

Medicine and Dentistry

• Anticoagulant Therapy 100%
• Vitamin K Antagonist 100%
• Pharmacogenetics 100%
• Antithrombotic 80%
• Genetic Screening 60%
• Coumarin Derivative 40%
• CYP2C9 40%
• Health Outcomes 20%
• Body Mass Index 20%
• Prematurity 20%
• Diseases 20%
• Thrombosis 20%
• Bleeding 20%
• Warfarin 20%
• Dose Response 20%
• Dietary Intake 20%
• Maintenance Drug Dose 20%
• Thrombin 20%
• Thromboembolism 20%
• DNA Polymorphism 20%
• Factor X 20%
• Vitamin K Epoxide Reductase 20%
• Pharmacogenetic Testing 20%
• Drug Competition 20%
• Drug Delivery System 20%
• Cost-Effectiveness Analysis 20%
• Comorbidity 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacogenetics 100%
• Antivitamin K 100%
• Anticoagulant Agent 80%
• Anticoagulation Therapy 40%
• Coumarin Derivative 40%
• CYP2C9 40%
• Maintenance Dose 20%
• Drug Delivery System 20%
• Prematurity 20%
• Bleeding 20%
• Thrombin 20%
• Thromboembolism 20%
• Blood Clotting Factor 10 20%
• Vitamin K Epoxide Reductase 20%
• Vitamin K Group 20%
• Disease 20%
• Thrombosis 20%
• Warfarin 20%
• Comorbidity 20%